Zobrazeno 1 - 10
of 158
pro vyhledávání: '"Thomas J, Ow"'
Publikováno v:
3D Printing in Medicine, Vol 9, Iss 1, Pp 1-6 (2023)
Abstract The customizability of 3D printing allows for the manufacturing of personalized medical devices such as laryngectomy tubes, but it is vital to establish the biocompatibility of printing materials to ensure that they are safe and durable. The
Externí odkaz:
https://doaj.org/article/a2269046c015441e9f43593d134ccfe5
Autor:
Kendra Smith, Rufa’i Umar Zubair, Richard V. Smith, Stelby Augustine, Nicholas F. Schlecht, Thomas J. Ow, Michael B. Prystowsky, Thomas J. Belbin
Publikováno v:
Biomedicines, Vol 12, Iss 11, p 2482 (2024)
Background: Novel ZNF genes, such as ZNF671, that are located on chromosome 19q13 are known to be hypermethylated at a high frequency in HNSCC as well as in other epithelial solid tumors. Their function is largely unknown. Results: Here, we show that
Externí odkaz:
https://doaj.org/article/b122705e422a4fb6a7dee70e930c6bda
Autor:
Kenneth R. Gundle, Karthik Rajasekaran, Jeffrey Houlton, Gary B. Deutsch, Thomas J. Ow, Robert G. Maki, John Pang, Cherie-Ann O. Nathan, Daniel Clayburgh, Jason G. Newman, Elyse Brinkmann, Michael J. Wagner, Seth M. Pollack, Matthew J. Thompson, Ryan J. Li, Vikas Mehta, Bradley A. Schiff, Barry I. Wenig, Paul L. Swiecicki, Alice L. Tang, Jessica L. Davis, Annemieke van Zante, Jessica A. Bertout, Wendy Jenkins, Atticus Turner, Marc Grenley, Connor Burns, Jason P. Frazier, Angela Merrell, Kimberly H. W. Sottero, Jonathan M. J. Derry, Kate C. Gillespie, Bre Mills, Richard A. Klinghoffer
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Introduction: Drug development is systemically inefficient. Research and development costs for novel therapeutics average hundreds of millions to billions of dollars, with the overall likelihood of approval estimated to be as low as 6.7% for oncology
Externí odkaz:
https://doaj.org/article/df356ddd88154387999a5c867f337370
Autor:
Luca Paoluzzi, Thomas J Ow
Publikováno v:
Current Oncology, Vol 28, Iss 1, Pp 574-580 (2021)
Immunotherapies directed at T-cell activation through antibodies targeting checkpoint proteins, such as programmed cell death 1 (PD1), are rapidly becoming the new standard of care in the treatment of several malignancies. Cemiplimab is a monoclonal
Externí odkaz:
https://doaj.org/article/043cf9e05600458682359646e43a72d5
Autor:
Henry James Foster, Thomas J. Ow, Danielle Bottalico, Gorthey Scott, Berrin Ustun, Keivan Shifteh
Publikováno v:
Clinical Case Reports, Vol 9, Iss 9, Pp n/a-n/a (2021)
Abstract Inflammatory myofibroblastic tumor is usually a benign tumor of mesenchymal origin that is rarely found in the larynx. This case explores the unique laryngeal location and presentation of this tumor as well as the challenging radiographic an
Externí odkaz:
https://doaj.org/article/f9469866ace04f8486476e192e57a5bc
Autor:
Cecelia E. Schmalbach, Thomas J. Ow, Karen Y. Choi, Miriam O'Leary, Alice Lin, Brian B. Hughley, Kevin S. Emerick, Brian Moore, Nancy Y. Lee, Dan P. Zandberg, Steven J. Wang
Publikováno v:
Head & Neck. 45:32-41
A position statement put forth by the American Head and Neck Society (AHNS) was constructed to provide evidence-based treatment recommendations for PD-1 inhibitor use in advanced cutaneous squamous cell carcinoma (cSCC). Secondarily, we sought to ide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::637db4b00d3d88ebe5de15cb89f5f8ec
https://doi.org/10.1002/hed.27202
https://doi.org/10.1002/hed.27202
Autor:
Stephen Y. Lai, Jeffrey N. Myers, James A. Bankson, Thomas J. Ow, Cristina T. Dodge, Yunyun Chen, Yuan Wang, Heath D. Skinner, Vlad C. Sandulache
PDF file, 55KB.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d09a6617ebb394e69a473c5c218415ad
https://doi.org/10.1158/1535-7163.22497742.v1
https://doi.org/10.1158/1535-7163.22497742.v1
Autor:
Thomas J. Ow, Evripidis Gavathiotis, Nicolas F. Schlecht, Michael B. Prystowsky, Jeffrey E. Segall, Carlos Thomas, Nitisha Shrivastava, Daniel Li, Cory D. Fulcher, Nicholas J. Gadsden
Supplementary Figure 1 shows phosphorylated-retinoblastoma protein (p-Rb) and retinoblastoma protein (Rb) expression after incubation with palbociclib among the panel of head and neck squamous cell carcinoma (HNSCC) lines. Supplementary Figure 2 show
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::713d3779f332716e6ea1ad8692649d85
https://doi.org/10.1158/1541-7786.22526021
https://doi.org/10.1158/1541-7786.22526021
Autor:
Stephen Y. Lai, Jeffrey N. Myers, James A. Bankson, Thomas J. Ow, Cristina T. Dodge, Yunyun Chen, Yuan Wang, Heath D. Skinner, Vlad C. Sandulache
PDF file, 810KB.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4667d6099dee70d9ff929be0380606b
https://doi.org/10.1158/1535-7163.22497745
https://doi.org/10.1158/1535-7163.22497745
Autor:
Thomas J. Ow, Evripidis Gavathiotis, Nicolas F. Schlecht, Michael B. Prystowsky, Jeffrey E. Segall, Carlos Thomas, Nitisha Shrivastava, Daniel Li, Cory D. Fulcher, Nicholas J. Gadsden
We demonstrate that inhibition of cyclin-dependent kinases 4/6 (CDK4/6) leads to senescence in human papillomavirus (HPV)–negative (−) head and neck squamous cell carcinoma (HNSCC), but not in HPV-positive (+) HNSCC. The BCL-2 family inhibitor, n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::896459acd41aaf17a9d8d7884ff25ec6
https://doi.org/10.1158/1541-7786.c.6544985.v1
https://doi.org/10.1158/1541-7786.c.6544985.v1